baclofen has been researched along with Parkinson Disease in 9 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A new less invasive treatment of tremor using MR guided focused ultrasound has started and is promising." | 2.49 | [Role of neurosurgical management in movement disorders other than Parkinson disease]. ( Taira, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taira, T | 1 |
| Hajj, R | 1 |
| Milet, A | 1 |
| Toulorge, D | 1 |
| Cholet, N | 1 |
| Laffaire, J | 1 |
| Foucquier, J | 1 |
| Robelet, S | 1 |
| Mitry, R | 1 |
| Guedj, M | 1 |
| Nabirotchkin, S | 1 |
| Chumakov, I | 1 |
| Cohen, D | 1 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| Moutoussis, M | 1 |
| Orrell, W | 1 |
| Volpi, R | 2 |
| Chiodera, P | 2 |
| Caffarra, P | 2 |
| Scaglioni, A | 2 |
| Saccani, A | 1 |
| Coiro, V | 2 |
| Lees, AJ | 2 |
| Clarke, CR | 1 |
| Harrison, MJ | 1 |
| Shaw, KM | 1 |
| Stern, GM | 1 |
| Gerlach, J | 1 |
| Marcato, A | 1 |
| Rossi, G | 1 |
| Caffarri, G | 1 |
| Delsignore, R | 1 |
1 review available for baclofen and Parkinson Disease
| Article | Year |
|---|---|
[Role of neurosurgical management in movement disorders other than Parkinson disease].
Topics: Baclofen; Deep Brain Stimulation; Dystonia; Humans; Injections, Spinal; Movement Disorders; Muscle S | 2013 |
3 trials available for baclofen and Parkinson Disease
| Article | Year |
|---|---|
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Different control mechanisms of growth hormone (GH) secretion between gamma-amino- and gamma-hydroxy-butyric acid: neuroendocrine evidence in Parkinson's disease.
Topics: Aged; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male; M | 1997 |
Baclofen in Parkinson's disease.
Topics: Aged; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Indu | 1978 |
5 other studies available for baclofen and Parkinson Disease
| Article | Year |
|---|---|
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Baclofen therapy for rigidity associated with Lewy body dementia.
Topics: Aged; Aged, 80 and over; Baclofen; Dementia; Female; GABA Agonists; Humans; Muscle Rigidity; Neurolo | 1996 |
Hallucinations after withdrawal of baclofen.
Topics: Aminobutyrates; Baclofen; Hallucinations; Humans; Male; Middle Aged; Parkinson Disease; Substance Wi | 1977 |
The relationship between parkinsonism and tardive dyskinesia.
Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug | 1977 |
Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in Parkinson's disease.
Topics: Aged; Baclofen; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male; Middle Aged; Parkinson Diseas | 1991 |